Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
Rhea-AI Summary
Bluejay Diagnostics (NASDAQ: BJDX) reported Q2 2026 results and operational progress, highlighting advancement of its Symphony™ IL-6 rapid diagnostic platform. The company completed targeted enrollment of 750 hospital patients in its SYMON-II pivotal clinical validation study and is moving into analytical and clinical validation to support a planned FDA 510(k) submission.
According to Bluejay, a US manufacturing contract has been signed to mitigate supply-chain risk as the company prepares for potential commercialization. The company ended June 30, 2026 with approximately $9.6 million in cash and cash equivalents, up from about $5.2 million at December 31, 2025, supported by roughly $7.7 million of net cash from financing in the first half, including about $7.6 million from a June 2026 private placement. Current cash resources are estimated to fund operations through the second quarter of 2027. Symphony remains an investigational device, limited by US law to investigational use.
Positive
- SYMON-II pivotal trial reached targeted enrollment of 750 patients
- Cash balance rose to $9.6 million at June 30, 2026 from $5.2 million
- Generated approximately $7.7 million net cash from financing in first half 2026
- June 2026 private placement provided about $7.6 million in net proceeds
- US manufacturing contract signed to support Symphony supply and commercialization readiness
- Cash resources estimated to fund operations through Q2 2027
Negative
- Symphony platform and IL-6 test remain investigational and not yet FDA cleared
- Disclosed cash runway only extends through the second quarter of 2027
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 21 | Clinical enrollment completion | Positive | -4.1% | SYMON-II reached its 750-patient enrollment target |
| Jun 05 | Private placement closing | Negative | +9.0% | Private placement generated $8.5 million in gross proceeds |
| Jun 02 | Private placement announcement | Negative | +100.0% | Offering included potential additional warrant proceeds |
| Jun 02 | Manufacturing partnership | Positive | +100.0% | Argonaut partnership targeted U.S.-based scalable manufacturing |
| May 07 | Corporate update | Negative | -5.5% | Update cited cash resources and ongoing 510(k) preparation |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
BJDX historically diverged from positive clinical and financing announcements more often than it aligned with them.
Key Terms
il-6 medical
pivotal clinical validation study medical
510(k) regulatory
private placement financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
- SYMON-II pivotal clinical study completes targeted enrollment of 750 patients
- Company advances toward planned 510(k) submission and commercialization with US manufacturing contract signed to mitigate supply-chain risk
- Company ends second quarter with approximately
$9.6 million in cash following significant financing
ACTON, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company focused on improving patient outcomes in critical care settings, today reported financial results for the quarter ended June 30, 2026 and provided an update on the Company’s clinical, regulatory and manufacturing progress.
During the first half of 2026, Bluejay continued to advance several key elements of its development strategy for the Symphony™ platform and its lead product candidate, the Symphony IL-6 test. The Company completed the targeted enrollment of 750 hospital patients in its SYMON-II pivotal clinical validation study and is progressing toward analytical and clinical validation activities intended to support a future FDA 510(k) submission.
At June 30, 2026, Bluejay had approximately
“We believe the second quarter represented an important period of execution for Bluejay as we strengthened our financial position while continuing to advance the clinical, regulatory and manufacturing infrastructure required for Symphony,” said Neil Dey, President and Chief Executive Officer of Bluejay Diagnostics. “With targeted enrollment of 750 patients in SYMON-II now completed, our focus is increasingly shifting towards manufacturing readiness and the activities necessary to support our planned regulatory submission and commercialization.”
Dey continued, “Importantly, we believe our recent financing provides us with additional resources to execute these near-term priorities. We ended the quarter with approximately
Note: The Company's Symphony™ rapid diagnostic platform is an investigational device and is limited by United States law to investigational use.
About the SYMON Clinical Study Program:
The SYMON Clinical Study Program includes SYMON-I (clinicaltrials.gov ID NCT06181604), SYMON-II (NCT06654895), and SYMON-III (NCT07425587). SYMON-I is a pilot study to determine IL-6 levels associated with various endpoints, including, but not limited to 28-day all-cause mortality and in-hospital mortality. The SYMON-II study is the pivotal study to validate the outcomes of the SYMON-I study, which the Company plans to use to support a 510(k) application to the FDA. The SYMON-III study is a pilot study to determine IL-6 levels associated with patients presenting with increasing severity of infection in the emergency department and risk of developing sepsis.
About Bluejay Diagnostics:
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.
Forward-Looking Statements:
This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and in Part II, Item 1A, “Risk Factors” in its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2026 and June 30, 2026. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events, except as required by law.
Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
ir@bluejaydx.com
Website: www.bluejaydx.com
